Is Alkermes Plc (ALKS) overvalued? · P/E 14, rev $1.56B
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Alkermes Plc (ALKS) looks expensive on cached numbers — not a short thesis.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ALKS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ALKS stock page for the full model, not this heading.
Not investment advice.